Reaktionsgleichung
Cl[C:2]1[N:22]=[C:5]2[C:6]([C:10]3[CH:15]=[C:14]([C:16]([F:19])([F:18])[F:17])[CH:13]=[CH:12][C:11]=3[O:20][CH3:21])=[CH:7][CH:8]=[CH:9][N:4]2[N:3]=1.[C:23]([O:27][C:28]([N:30]1[CH2:35][CH2:34][N:33]([C:36]2[CH:41]=[CH:40][CH:39]=[C:38]([NH2:42])[CH:37]=2)[CH2:32][CH2:31]1)=[O:29])([CH3:26])([CH3:25])[CH3:24]>>[C:23]([O:27][C:28]([N:30]1[CH2:35][CH2:34][N:33]([C:36]2[CH:41]=[CH:40][CH:39]=[C:38]([NH:42][C:2]3[N:22]=[C:5]4[C:6]([C:10]5[CH:15]=[C:14]([C:16]([F:19])([F:18])[F:17])[CH:13]=[CH:12][C:11]=5[O:20][CH3:21])=[CH:7][CH:8]=[CH:9][N:4]4[N:3]=3)[CH:37]=2)[CH2:32][CH2:31]1)=[O:29])([CH3:26])([CH3:24])[CH3:25]Komponenten
Edukt 2
Produkt 1
Versuchsvorschrift
4-(3-[8-(2-methoxy-5-trifloromethylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl)-piperazine-1-carboxylic acid tert-butyl ester was prepared from 2-chloro-8-(2-methoxy-5-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridine (0.150 g, 0.5 mmol), and 4-(3-amino-phenyl)piperazine-1-carboxylic acid tert-butyl ester (0.152 g, 0.548 mmol) in a manner analogous to Example 2d. Product was isolated as a foam (0.19 g, 73%). 1H NMR (400 MHz, CDCl3, δ, ppm): 8.47 (d, J=6.1 Hz, 1H), 7.93 (s, 1H), 7.69 (d, J=8.1 Hz, 1H), 7.56 (d, J=6.1 Hz, 1H), 7.46-7.40 (m, 2H), 7.31-7.28 (m, 1H), 7.13 (d, J=8.1 Hz, 1H), 7.00-6.94 (m, 1H), 6.87 (s, 1H), 6.84 (d, J=8.1 Hz, 1H), 3.88 (s, 3H), 2.89-2.75 (m, 2H), 2.73-2.63 (m, 1H), 1.92-1.79 (m, 2H), 1.73-1.63 (m, 4H), 1.52 (s, 9H). MS=568 (MH)+.
Quellen und Nachweise
- ORD-Eintrag
- ord-1847a7e4f33b427f8dafbdffefbde47c
- Quelldatensatz
- uspto-grants-2014_01
- Patentnummer
- US08633173B2
Verknüpfte Notizen
Wird geladen…